Dr Martin brings with him 20 years of experience in the biotechnology industry. Before joining Dynavax Technologies, Dr Martin served as a president of Humabs.
Prior to that Dr Martin was vice president of development at Chiron for seven years. At Chiron he led the team responsible for the development of the new vaccine adjuvant MF59 that was licensed by regulatory agencies since alum, and approved as FLUAD influenza vaccine in Europe.
Dr Martin has also held senior development and research positions at Sangamo, Valentis and SyStemix/GTI.
Dino Dina, CEO of Dynavax Technologies, said: “Tyler has made many contributions to advancing the Dynavax Technologies’ programs since joining us a little more than a year ago, including leading the effort to remove the clinical hold on Heplisav, reinitiating clinical development and moving our new universal flu vaccine product candidate into the clinic. We look forward to his continuing achievements in his new role.”